About Terns Pharmaceuticals Inc.

Terns Pharmaceuticals Inc., founded in 2016, is dedicated to developing novel therapies for patients with serious liver diseases where current treatment options are limited or nonexistent. The company has built a focused pipeline targeting the growing epidemic of liver disease globally. TERN stock price reflects investor interest in the company's liver disease focus and advancing clinical programs.

Led by CEO Senthil Sundaram, Terns has assembled a team with deep expertise in liver disease and drug development to advance its clinical pipeline. The management team combines hepatology expertise with proven pharmaceutical development capabilities. Leadership's strategic focus on liver diseases with significant unmet medical needs has been important for building a differentiated pipeline and influencing TERN stock price trajectory.

Terns operates by developing therapies for nonalcoholic steatohepatitis (NASH), liver fibrosis, and other chronic liver diseases using novel mechanisms of action and combination approaches. The company's pipeline includes programs in various stages of clinical development targeting different aspects of liver disease progression. With liver disease representing a growing global health challenge, limited current treatment options creating significant unmet needs, and Terns' focused expertise in hepatology, TERN offers investors exposure to liver disease therapeutics with potential for meaningful patient impact and commercial success in large and underserved patient populations.